Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force
Combination therapy is expected to play an important role for the treatment of Alzheimer’s disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer’s Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and logistical challenges to th...
Gespeichert in:
| Veröffentlicht in: | The Journal of Prevention of Alzheimer's Disease 2019-01, Vol.6 (3), p.164-168 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 168 |
|---|---|
| container_issue | 3 |
| container_start_page | 164 |
| container_title | The Journal of Prevention of Alzheimer's Disease |
| container_volume | 6 |
| creator | Gauthier, Serge Alam, J. Fillit, H. Iwatsubo, T. Liu-Seifert, H. Sabbagh, M. Salloway, S. Sampaio, C. Sims, J. R. Sperling, B. Sperling, R. Welsh-Bohmer, K. A. Touchon, J. Vellas, B. Aisen, P. |
| description | Combination therapy is expected to play an important role for the treatment of Alzheimer’s disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer’s Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and logistical challenges to the development of combination therapy for AD and current efforts to address these challenges. Task Force members unanimously agreed that successful treatment of AD will likely require combination therapy approaches that target multiple mechanisms and pathways. They further agreed on the need for global collaboration and sharing of data and resources to accelerate development of such approaches. |
| doi_str_mv | 10.14283/jpad.2019.12 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04605590v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2232116424</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-bf9f084afe6dce56294efffa6fc95fc59d6b8dece8701c155c1231e3225edf063</originalsourceid><addsrcrecordid>eNp1kD1PwzAQQC0EAlQYWZFHGFLsS-wmbFXLl1QJJFqJzXKdM01J4mCnSDDxN_h7_BJSCmxMPvmenk6PkCPO-jyBND5bNjrvA-NZn8MW2YcEZMRAyu1uhkESiZQN9shhCEvGOorLOEt3yV7MmYQU5D55GLlqXtS6LVxNpwv0unml1nk6LN8WWFToP98_Ah0XAXXAc3qHPjRo2uIFA3WWtgukF7Oz2T0dTYdjOtXhiV46b_CA7FhdBjz8eXtkdnkxHV1Hk9urm9FwEplYyjaa28yyNNEWZW5QSMgStNZqaU0mrBFZLudpjgbTAeOGC2E4xBxjAIG5ZTLukdONd6FL1fii0v5VOV2o6-FErf9YIpkQGXvhHXuyYRvvnlcYWlUVwWBZ6hrdKiiAGDiXCSQdGm1Q410IHu2fmzP13V6t26t1e9Wd1CPHP-rVvML8j_4t3QH9DRC6Vf2IXi3dytddmn-MXwnHjmE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2232116424</pqid></control><display><type>article</type><title>Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force</title><source>Springer Nature - Complete Springer Journals</source><creator>Gauthier, Serge ; Alam, J. ; Fillit, H. ; Iwatsubo, T. ; Liu-Seifert, H. ; Sabbagh, M. ; Salloway, S. ; Sampaio, C. ; Sims, J. R. ; Sperling, B. ; Sperling, R. ; Welsh-Bohmer, K. A. ; Touchon, J. ; Vellas, B. ; Aisen, P.</creator><creatorcontrib>Gauthier, Serge ; Alam, J. ; Fillit, H. ; Iwatsubo, T. ; Liu-Seifert, H. ; Sabbagh, M. ; Salloway, S. ; Sampaio, C. ; Sims, J. R. ; Sperling, B. ; Sperling, R. ; Welsh-Bohmer, K. A. ; Touchon, J. ; Vellas, B. ; Aisen, P.</creatorcontrib><description>Combination therapy is expected to play an important role for the treatment of Alzheimer’s disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer’s Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and logistical challenges to the development of combination therapy for AD and current efforts to address these challenges. Task Force members unanimously agreed that successful treatment of AD will likely require combination therapy approaches that target multiple mechanisms and pathways. They further agreed on the need for global collaboration and sharing of data and resources to accelerate development of such approaches.</description><identifier>ISSN: 2274-5807</identifier><identifier>EISSN: 2426-0266</identifier><identifier>DOI: 10.14283/jpad.2019.12</identifier><identifier>PMID: 31062826</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>CTAD Task Force Paper ; Geriatrics/Gerontology ; Life Sciences ; Medicine ; Medicine & Public Health ; Neurology</subject><ispartof>The Journal of Prevention of Alzheimer's Disease, 2019-01, Vol.6 (3), p.164-168</ispartof><rights>Serdi and Springer Nature Switzerland AG 2019</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-bf9f084afe6dce56294efffa6fc95fc59d6b8dece8701c155c1231e3225edf063</citedby><cites>FETCH-LOGICAL-c366t-bf9f084afe6dce56294efffa6fc95fc59d6b8dece8701c155c1231e3225edf063</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.14283/jpad.2019.12$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.14283/jpad.2019.12$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31062826$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://ut3-toulouseinp.hal.science/hal-04605590$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Gauthier, Serge</creatorcontrib><creatorcontrib>Alam, J.</creatorcontrib><creatorcontrib>Fillit, H.</creatorcontrib><creatorcontrib>Iwatsubo, T.</creatorcontrib><creatorcontrib>Liu-Seifert, H.</creatorcontrib><creatorcontrib>Sabbagh, M.</creatorcontrib><creatorcontrib>Salloway, S.</creatorcontrib><creatorcontrib>Sampaio, C.</creatorcontrib><creatorcontrib>Sims, J. R.</creatorcontrib><creatorcontrib>Sperling, B.</creatorcontrib><creatorcontrib>Sperling, R.</creatorcontrib><creatorcontrib>Welsh-Bohmer, K. A.</creatorcontrib><creatorcontrib>Touchon, J.</creatorcontrib><creatorcontrib>Vellas, B.</creatorcontrib><creatorcontrib>Aisen, P.</creatorcontrib><title>Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force</title><title>The Journal of Prevention of Alzheimer's Disease</title><addtitle>J Prev Alzheimers Dis</addtitle><addtitle>J Prev Alzheimers Dis</addtitle><description>Combination therapy is expected to play an important role for the treatment of Alzheimer’s disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer’s Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and logistical challenges to the development of combination therapy for AD and current efforts to address these challenges. Task Force members unanimously agreed that successful treatment of AD will likely require combination therapy approaches that target multiple mechanisms and pathways. They further agreed on the need for global collaboration and sharing of data and resources to accelerate development of such approaches.</description><subject>CTAD Task Force Paper</subject><subject>Geriatrics/Gerontology</subject><subject>Life Sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neurology</subject><issn>2274-5807</issn><issn>2426-0266</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp1kD1PwzAQQC0EAlQYWZFHGFLsS-wmbFXLl1QJJFqJzXKdM01J4mCnSDDxN_h7_BJSCmxMPvmenk6PkCPO-jyBND5bNjrvA-NZn8MW2YcEZMRAyu1uhkESiZQN9shhCEvGOorLOEt3yV7MmYQU5D55GLlqXtS6LVxNpwv0unml1nk6LN8WWFToP98_Ah0XAXXAc3qHPjRo2uIFA3WWtgukF7Oz2T0dTYdjOtXhiV46b_CA7FhdBjz8eXtkdnkxHV1Hk9urm9FwEplYyjaa28yyNNEWZW5QSMgStNZqaU0mrBFZLudpjgbTAeOGC2E4xBxjAIG5ZTLukdONd6FL1fii0v5VOV2o6-FErf9YIpkQGXvhHXuyYRvvnlcYWlUVwWBZ6hrdKiiAGDiXCSQdGm1Q410IHu2fmzP13V6t26t1e9Wd1CPHP-rVvML8j_4t3QH9DRC6Vf2IXi3dytddmn-MXwnHjmE</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Gauthier, Serge</creator><creator>Alam, J.</creator><creator>Fillit, H.</creator><creator>Iwatsubo, T.</creator><creator>Liu-Seifert, H.</creator><creator>Sabbagh, M.</creator><creator>Salloway, S.</creator><creator>Sampaio, C.</creator><creator>Sims, J. R.</creator><creator>Sperling, B.</creator><creator>Sperling, R.</creator><creator>Welsh-Bohmer, K. A.</creator><creator>Touchon, J.</creator><creator>Vellas, B.</creator><creator>Aisen, P.</creator><general>Springer International Publishing</general><general>SERDI éd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>1XC</scope></search><sort><creationdate>20190101</creationdate><title>Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force</title><author>Gauthier, Serge ; Alam, J. ; Fillit, H. ; Iwatsubo, T. ; Liu-Seifert, H. ; Sabbagh, M. ; Salloway, S. ; Sampaio, C. ; Sims, J. R. ; Sperling, B. ; Sperling, R. ; Welsh-Bohmer, K. A. ; Touchon, J. ; Vellas, B. ; Aisen, P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-bf9f084afe6dce56294efffa6fc95fc59d6b8dece8701c155c1231e3225edf063</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>CTAD Task Force Paper</topic><topic>Geriatrics/Gerontology</topic><topic>Life Sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neurology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gauthier, Serge</creatorcontrib><creatorcontrib>Alam, J.</creatorcontrib><creatorcontrib>Fillit, H.</creatorcontrib><creatorcontrib>Iwatsubo, T.</creatorcontrib><creatorcontrib>Liu-Seifert, H.</creatorcontrib><creatorcontrib>Sabbagh, M.</creatorcontrib><creatorcontrib>Salloway, S.</creatorcontrib><creatorcontrib>Sampaio, C.</creatorcontrib><creatorcontrib>Sims, J. R.</creatorcontrib><creatorcontrib>Sperling, B.</creatorcontrib><creatorcontrib>Sperling, R.</creatorcontrib><creatorcontrib>Welsh-Bohmer, K. A.</creatorcontrib><creatorcontrib>Touchon, J.</creatorcontrib><creatorcontrib>Vellas, B.</creatorcontrib><creatorcontrib>Aisen, P.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>The Journal of Prevention of Alzheimer's Disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gauthier, Serge</au><au>Alam, J.</au><au>Fillit, H.</au><au>Iwatsubo, T.</au><au>Liu-Seifert, H.</au><au>Sabbagh, M.</au><au>Salloway, S.</au><au>Sampaio, C.</au><au>Sims, J. R.</au><au>Sperling, B.</au><au>Sperling, R.</au><au>Welsh-Bohmer, K. A.</au><au>Touchon, J.</au><au>Vellas, B.</au><au>Aisen, P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force</atitle><jtitle>The Journal of Prevention of Alzheimer's Disease</jtitle><stitle>J Prev Alzheimers Dis</stitle><addtitle>J Prev Alzheimers Dis</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>6</volume><issue>3</issue><spage>164</spage><epage>168</epage><pages>164-168</pages><issn>2274-5807</issn><eissn>2426-0266</eissn><abstract>Combination therapy is expected to play an important role for the treatment of Alzheimer’s disease (AD). In October 2018, the European Union-North American Clinical Trials in Alzheimer’s Disease Task Force (EU/US CTAD Task Force) met to discuss scientific, regulatory, and logistical challenges to the development of combination therapy for AD and current efforts to address these challenges. Task Force members unanimously agreed that successful treatment of AD will likely require combination therapy approaches that target multiple mechanisms and pathways. They further agreed on the need for global collaboration and sharing of data and resources to accelerate development of such approaches.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>31062826</pmid><doi>10.14283/jpad.2019.12</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2274-5807 |
| ispartof | The Journal of Prevention of Alzheimer's Disease, 2019-01, Vol.6 (3), p.164-168 |
| issn | 2274-5807 2426-0266 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04605590v1 |
| source | Springer Nature - Complete Springer Journals |
| subjects | CTAD Task Force Paper Geriatrics/Gerontology Life Sciences Medicine Medicine & Public Health Neurology |
| title | Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T17%3A47%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Combination%20Therapy%20for%20Alzheimer%E2%80%99s%20Disease:%20Perspectives%20of%20the%20EU/US%20CTAD%20Task%20Force&rft.jtitle=The%20Journal%20of%20Prevention%20of%20Alzheimer's%20Disease&rft.au=Gauthier,%20Serge&rft.date=2019-01-01&rft.volume=6&rft.issue=3&rft.spage=164&rft.epage=168&rft.pages=164-168&rft.issn=2274-5807&rft.eissn=2426-0266&rft_id=info:doi/10.14283/jpad.2019.12&rft_dat=%3Cproquest_hal_p%3E2232116424%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2232116424&rft_id=info:pmid/31062826&rfr_iscdi=true |